
MosaMeat BV closes US$85m Series B financing
While EU policymakers are yet discussing the green deal or farm to fork strategies, Dutch MosaMeat BV is launching a new era of biotechnologically...

Novel strategy targets chronic liver diseases
The approach published in Nature Cancer leads to a cell-toxic accumulation of saturated fatty acids that drives tumour cells into apoptosis. HCC...

InteRNA Technologies secures €18.5m in Series B financing
Waterman Ventures and current shareholders Aglaia Oncology Funds and OostNL participated in the funding. The Utrecht-based...

Novo Holdings creates Hemab
Hemab ApS will combine antibody know-how from Genmab A/S and Novo Nordisk to fight medically underserved orphan bleeding disorders. The company...

Drug set to rescue COVID-19 patients at ICUs
Initial data from an US expanded access (EA) use of RLF-100™ (aviptadil) in 90 ICU patients with critical COVID-19 and severe comorbidities...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

Germany first EU country to launch COVID-19 therapy offensive?
"Besides protection by masks, social distancing etc, rapid diagnostic testing, and COVID-19 vaccines, we are now establishing a fourth pillar of...